Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Alonso R, Casas M, Lazaro L, Fernandez Liguori N, Pita C, Cohen L, Rojas JI, Pappolla A, Patrucco L, Cristiano E, Burgos M, Vrech C, Piedrabuena R, Pablo L, Deri N, Luetic G, Miguez J, Cabrera M, Martinez A, Zanga G, Tkachuk V, Tizio S, Carnero Contentti E, Knorre E, Leguizamon F, Mainella C, Nofal P, Liwacki S, Hryb J, Menichini M, Pestchanker C, Alonso M, Garcea O, Silva B.
Alonso R, et al. Among authors: rojas ji.
Mult Scler J Exp Transl Clin. 2023 Feb 22;9(1):20552173231154712. doi: 10.1177/20552173231154712. eCollection 2023 Jan-Mar.
Mult Scler J Exp Transl Clin. 2023.
PMID: 36846108
Free PMC article.